{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:20Z","timestamp":1792021640812,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ebiom.2024.105202","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:49:54Z","timestamp":1718891394000},"page":"105202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1505-5471","authenticated-orcid":false,"given":"Loris","family":"Roncali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Marionneau-Lambot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Eychenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Avril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-9257","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-2785","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Gu\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Hindr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ch\u00e9rel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0887-272X","authenticated-orcid":false,"given":"Emmanuel","family":"Garcion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2024.105202_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105202_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ebiom.2024.105202_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10495-018-1480-9","article-title":"Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma","volume":"23","author":"Taylor","year":"2018","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105202_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.ebiom.2024.105202_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/nox144","article-title":"Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma","volume":"20","author":"Mandel","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib8","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1016\/j.biomaterials.2011.05.067","article-title":"Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules","volume":"32","author":"Vanpouille-Box","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ebiom.2024.105202_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-016-2289-4","article-title":"Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model","volume":"131","author":"Cikankowitz","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib10","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.7150\/thno.19403","article-title":"Locoregional confinement and major clinical benefit of 188Re-loaded CXCR4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma","volume":"7","author":"S\u00e9h\u00e9dic","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ebiom.2024.105202_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","article-title":"Overview of the most promising radionuclides for targeted alpha therapy: the \u2018hopeful eight\u2019","volume":"13","author":"Eychenne","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ebiom.2024.105202_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064730","article-title":"Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation","volume":"8","author":"Wulbrand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2024.105202_bib13","first-page":"4719","article-title":"Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate","volume":"54","author":"Zalutsky","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2024.105202_bib14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2967\/jnumed.116.178327","article-title":"Cure of human ovarian carcinoma solid xenografts by fractionated \u03b1-radioimmunotherapy with 211At-MX35-F(ab')2: influence of absorbed tumor dose and effect on long-term survival","volume":"58","author":"B\u00e4ck","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ebiom.2024.105202_bib15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3390\/cancers12041017","article-title":"Preclinical targeted \u03b1- and \u03b2--radionuclide therapy in HER2-positive brain metastasis using camelid single-domain antibodies","volume":"12","author":"Puttemans","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ebiom.2024.105202_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ebiom.2024.105202_bib17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-010-1385-5","article-title":"Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial","volume":"37","author":"Cordier","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ebiom.2024.105202_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00259-018-4225-7","article-title":"Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma","volume":"46","author":"Kr\u00f3licki","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ebiom.2024.105202_bib19","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00259-021-05350-y","article-title":"Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy","volume":"48","author":"Kr\u00f3licki","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ebiom.2024.105202_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nucmedbio.2021.05.007","article-title":"Production, purification and availability of 211At: near term steps towards global access","volume":"100\u2013101","author":"Feng","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ebiom.2024.105202_bib21","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/acs.accounts.1c00327","article-title":"Advances in the chemistry of astatine and implications for the development of radiopharmaceuticals","volume":"54","author":"Gu\u00e9rard","year":"2021","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ebiom.2024.105202_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3413\/Nukmed-0580-13-05","article-title":"Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma","volume":"52","author":"Borrmann","year":"2013","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.ebiom.2024.105202_bib23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.18632\/oncotarget.27552","article-title":"Targeted alpha therapy using astatine (211At)-labeled phenylalanine: a preclinical study in glioma bearing mice","volume":"11","author":"Watabe","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2024.105202_bib24","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acs.molpharmaceut.2c00349","article-title":"Targeted alpha therapy of glioma using 211At-labeled heterodimeric peptide targeting both VEGFR and integrins","volume":"19","author":"Liu","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ebiom.2024.105202_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acsptsci.0c00206","article-title":"PARP targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma","volume":"4","author":"Dabagian","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.ebiom.2024.105202_bib26","first-page":"1","article-title":"Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy","volume":"19","author":"Kato","year":"2021","journal-title":"J\u00a0Nanobiotechnology"},{"key":"10.1016\/j.ebiom.2024.105202_bib27","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.2147\/IJN.S327577","article-title":"Gold nanostars: a novel platform for developing211at-labeled agents for targeted alpha-particle therapy","volume":"16","author":"Liu","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ebiom.2024.105202_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116600","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment","volume":"55","author":"Ma","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ebiom.2024.105202_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092721","article-title":"Targeted-Alpha-therapy combining astatine-211 and anti-cd138 antibody in A preclinical syngeneic mouse model of multiple myeloma minimal residual disease","volume":"12","author":"Gouard","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ebiom.2024.105202_bib30","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1111\/febs.14828","article-title":"Structures and interactions of syndecans","volume":"286","author":"Gondelaud","year":"2019","journal-title":"FEBS J"},{"key":"10.1016\/j.ebiom.2024.105202_bib31","doi-asserted-by":"crossref","first-page":"40922","DOI":"10.18632\/oncotarget.16733","article-title":"Syndecan-1 knockdown inhibits glioma cell proliferation and invasion by deregulating a c-src\/FAK-associated signaling pathway","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2024.105202_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.792443","article-title":"Weighted gene Co-expression network analysis (WGCNA) reveals the functions of syndecan-1 to regulate immune infiltration by influenced T cells in glioma","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.ebiom.2024.105202_bib33","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.7150\/thno.81999","article-title":"SDC1-TGM2-FLOT1-BHMT complex determines radiosensitivity of glioblastoma by influencing the fusion of autophagosomes with lysosomes","volume":"13","author":"Zeng","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ebiom.2024.105202_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0969-8043(01)00044-6","article-title":"Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields","volume":"55","author":"Lindegren","year":"2001","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.ebiom.2024.105202_bib35","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.bmc.2017.09.022","article-title":"Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies","volume":"25","author":"Gu\u00e9rard","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ebiom.2024.105202_bib36","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Hunt Bobo","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2024.105202_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","article-title":"Convection-enhanced drug delivery for glioblastoma: a review","volume":"151","author":"D'Amico","year":"2021","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ebiom.2024.105202_bib39","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1021\/acsomega.8b03679","article-title":"Radiotheranostics coupled between an At-211-Labeled RGD peptide and the corresponding radioiodine-labeled RGD peptide","volume":"4","author":"Ogawa","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ebiom.2024.105202_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(99)00206-0","article-title":"Radiotoxicity of systemically administered 211At-labeled human\/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis","volume":"45","author":"McLendon","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ebiom.2024.105202_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2020.08.028","article-title":"Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation\/chemotherapy in\u00a0vivo","volume":"494","author":"Le Reste","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ebiom.2024.105202_bib42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01.shk.0000184286.95493.78","article-title":"Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier","volume":"24","author":"Henry-Stanley","year":"2005","journal-title":"Shock"},{"key":"10.1016\/j.ebiom.2024.105202_bib43","doi-asserted-by":"crossref","first-page":"C289","DOI":"10.1152\/ajpcell.00039.2022","article-title":"Syndecan-1 in liver pathophysiology","volume":"323","author":"Reszegi","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ebiom.2024.105202_bib44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (Syndecan-1), a plasma cell marker: immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O'Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ebiom.2024.105202_bib45","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2014-11-612770","article-title":"Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model","volume":"125","author":"Green","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2024.105202_bib46","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2147\/OTT.S159913","article-title":"Delivery of bevacizumab by intracranial injection: assessment in glioma model","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ebiom.2024.105202_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2118-3","article-title":"Evaluation of TgH(CX3CR1-EGFP) mice implanted with mCherry-GL261 cells as an in\u00a0vivo model for morphometrical analysis of glioma-microglia interaction","volume":"16","author":"Resende","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ebiom.2024.105202_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jocn.2020.11.025","article-title":"A\u00a0systematic review of multifocal and multicentric glioblastoma","volume":"83","author":"Li","year":"2021","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.ebiom.2024.105202_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-023-03325-4","article-title":"Targeting the neural stem cells in subventricular zone for the treatment of glioblastoma: an update from preclinical evidence to clinical interventions","volume":"14","author":"Li","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ebiom.2024.105202_bib50","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.4049\/jimmunol.1300931","article-title":"Syndecan-1, a cell surface proteoglycan, negatively regulates initial leukocyte recruitment to the brain across the choroid plexus in murine experimental autoimmune encephalomyelitis","volume":"191","author":"Zhang","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ebiom.2024.105202_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101784","article-title":"Syndecan-1 stimulates adult neurogenesis in the mouse ventricular-subventricular zone after injury","volume":"23","author":"Mouthon","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ebiom.2024.105202_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-005-9010-3","article-title":"Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression","volume":"77","author":"Watanabe","year":"2006","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib53","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/febs.12109","article-title":"Proteoglycans and their roles in brain cancer","volume":"280","author":"Wade","year":"2013","journal-title":"FEBS J"},{"key":"10.1016\/j.ebiom.2024.105202_bib54","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.3390\/ijms22084227","article-title":"Syndecan-1 (CD138), carcinomas and EMT","volume":"22","author":"Couchman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2024.105202_bib55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neo.2014.04.002","article-title":"Antitumor immunity induced after \u03b1 irradiation","volume":"16","author":"Gorin","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.ebiom.2024.105202_bib56","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2021.10.013","article-title":"Targeted alpha particle therapy remodels the tumor microenvironment and improves efficacy of immunotherapy","volume":"112","author":"Perrin","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ebiom.2024.105202_bib57","article-title":"Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy","volume":"9","author":"Lejeune","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ebiom.2024.105202_bib58","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.clgc.2017.10.010","article-title":"Immune analysis of radium-223 in patients with metastatic prostate cancer","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ebiom.2024.105202_bib59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5114\/jcb.2019.88138","article-title":"Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report","volume":"11","author":"Bellia","year":"2019","journal-title":"J\u00a0Contemp Brachytherapy"},{"key":"10.1016\/j.ebiom.2024.105202_bib60","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2967\/jnumed.116.173559","article-title":"Remodeling the vascular microenvironment of glioblastoma with \u03b1-particles","volume":"57","author":"Behling","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ebiom.2024.105202_bib61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding subset diversity in T cell memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2024.105202_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1501137","article-title":"Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models","volume":"7","author":"Genoud","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ebiom.2024.105202_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40824-022-00290-6","article-title":"Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy\/chemodynamic therapy to discourage cancer progression","volume":"26","author":"Zhang","year":"2022","journal-title":"Biomater Res"},{"key":"10.1016\/j.ebiom.2024.105202_bib64","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2024.105202_bib65","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ebiom.2024.105202_bib66","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/pharmaceutics15071926","article-title":"DNA repair inhibitors: potential targets and partners for targeted radionuclide therapy","volume":"15","author":"Obata","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ebiom.2024.105202_bib67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma \u2014 taking the fight to the tumour","volume":"18","author":"van Solinge","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2024.105202_bib68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ird3.30","article-title":"Alpha-emitters and targeted alpha therapy in cancer treatment","volume":"1","author":"Zhang","year":"2023","journal-title":"iRADIOLOGY"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424002378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424002378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:52:56Z","timestamp":1726753976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424002378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":68,"alternative-id":["S2352396424002378"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105202","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105202"}}